Scotiabank analyst Louise Chen downgraded Edgewise Therapeutics (EWTX) to Sector Perform from Outperform with a $14 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise Therapeutics 9.935M share Spot Secondary priced at $20.13
- Edgewise Therapeutics Announces $200M Stock Offering
- Edgewise Therapeutics Announces Positive Phase 2 Trial Results
- Edgewise Therapeutics announces top-line data of EDG-7500 from CIRRUS-HCM trial
- Buy Rating for Edgewise Therapeutics: Potential of EDG-7500 in Diverse HCM Patient Group Despite AF Concerns
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue